Cipla

Stocks to buy: Ajit Mishra of Religare Broking recommends buying BSE and Laurus Labs; also suggests Nifty trading strategy

Cipla declined 2% to ₹1,195.15, also its lowest level since December 2023 on the BSE in Wednesday's intra-day trade.

Ajit Mishra of Religare Broking recommends buying Cummins India, Granules and selling Cipla futures; check all details here

There are hopes of a turnaround in overall corporate earnings after six quarters of single digit growth

Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand

Cipla share price fell 2.4 per cent to the day's low of ₹1,335.90 per share on the National Stock Exchange (NSE)

Stocks to Watch today, February 23, 2026: From IDFC First Bank to Zee Entertainment, here is a list of shares that will be in focus

Bata India, Indian Hotels, IGL, MGL, Just Dial, Kalyan Jewellers, Jubilant FoodWorks, Oberoi Realty, Mankind Pharma and Suzlon Energy have hit their respective 52-week lows.

In Q3, Cipla's net profit dropped 57 per cent year-on-year (Y-o-Y) to ₹675 crore, as compared to ₹1,570.51 crore a year ago

Drugmakers Sun Pharma and Cipla are recalling products in the US due to manufacturing related issues, according to the US Food and Drug Administration. As per its latest Enforcement Report, the US-based arm of Mumbai-based Sun Pharma is recalling over 26,000 bottles of a generic medication to treat dandruff and skin conditions with inflammation and itching. The Princeton (New Jersey)-based Sun Pharmaceutical Industries Inc is recalling 24,624 bottles of Fluocinolone Acetonide Solution Topical Solution for "Failed Impurities/Degradation Specifications", the US health regulator said. The company initiated the Class III nationwide (US) recall on December 30, 2025. The US Food and Drug Administration (USFDA) noted that the company is also recalling certain batches of a medication to treat acne vulgaris. Sun Pharmaceutical Industries Inc initiated the Class III recall of Clindamycin Phosphate USP on November 26, 2025 due to "Failed Impurities/Degradation: Out of Specification results f

Bets on respiratory product launches and peptides for growth

Cipla Q3 Results: The decline in Cipla's profit was primarily due to a production halt at the exclusive manufacturer of Lanreotide, the company's second-largest revenue-contributing tumour drug

Q3FY26 company results: Firms including IndusInd Bank, Adani Green Energy, Godrej Consumer Products, India Cements, and JSW Energy are also to release their October-December earnings reports today

Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations

In the past seven trading days, the stock price of Cipla has slipped 11 per cent from ₹1,530.25 hit on January 1, 2026.

Stocks to Watch today, January 8, 2026: From Tata Steel to Cipla, here is a list of stocks that will be on investors' radar

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an awareness drive on insulin adherence

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk